MBOT, US59503A2042

Citizens JMP starts coverage of Microbot Medical stock at USD 2.50 target

Published on 10/24/2026 at 20:32 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue was USD 0.24 million on August 11, 2026. Microbot Medical stock was USD 0.97 on October 23, 2026, up 3.40 percent versus USD 0.94.

Citizens JMP target and results

Citizens JMP initiated coverage with a USD 2.50 target on October 23, 2026.
Microbot Medical reported USD 0.24 million in second-quarter revenue and a USD 5.60 million net loss.
Microbot Medical stock was USD 0.97 on October 23, 2026, up 3.40 percent from USD 0.94.

MBOT, US59503A2042, Illustration mit AI erstellt.

Microbot Medical (ISIN US59503A2042) received a new analyst rating from Citizens JMP on October 23, 2026, with a Market Outperform recommendation and a USD 2.50 price target. According to MarketBeat, the target was issued when Citizens JMP initiated coverage of the medical device company. Microbot Medical stock was USD 0.97 on October 23, 2026 at 4:00 p.m. ET, up 3.40 percent from the USD 0.94 prior close.

Revenue reached USD 0.24 million

Microbot Medical reported USD 0.24 million in revenue for the second quarter of 2026, compared with a USD 0.13 million consensus estimate. The company recorded a USD 5.60 million net loss, or USD 0.08 per share, for the same period. Investing.com reported that revenue exceeded H.C. Wainwright's USD 0.22 million forecast, while the net loss was larger than the firm's USD 4.00 million estimate.

Stock remains near its yearly low

Microbot Medical's Nasdaq quote stood within a USD 0.93 to USD 2.86 52-week range on October 23, 2026. The USD 0.97 price was USD 1.89 below the yearly high and USD 0.04 above the yearly low. Trading volume reached 568,460 shares, against an average volume of 664,837 shares.

Analyst targets remain widely spread

Citizens JMP's USD 2.50 target followed H.C. Wainwright's October 21, 2026 reiteration of a Buy rating and a USD 12.00 target, as reported by Investing.com. The two targets imply materially different views of Microbot Medical's commercialization path. The company develops the LIBERTY endovascular robotic system and reported that it is expanding customer and international distribution activity in 2026.

What investors can quantify

The latest reported quarter combined USD 0.24 million of revenue with a USD 5.60 million net loss, leaving commercialization progress as the central operating measure. The analyst range also remains broad, from USD 2.50 to USD 12.00, while the stock's October 23, 2026 close was USD 0.94.